DiaMedica Inc. (TSX-V: DMA) is pleased to announce the presentation of new compelling Type 2 diabetes data from studies of DM-204 at the Windhover Therapeutic Area Partnership Conference in Boston, MA, USA.
In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Treatment with DM-204 resulted in statistically significant lower mean differences compared to untreated animals after 21 days for the following parameters:
2.6% (p=0.0103) lower HbA1c levels at day 21
70% (p=0.0058) lower difference in fasting blood glucose levels
25 mm/Hg (p=0.0004) lower difference in systolic blood pressure levels
>20% (p=0.0156) improvement in total cholesterol levels
“These results are very encouraging and provide a strong foundation with which to move DM-204 forward,” said Dr. John Amatruda, DiaMedica’s Scientific Advisory Board member and former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories.
“DM-204 has the opportunity to fundamentally change the treatment regimen for Type 2 diabetes patients with hypertension and high cholesterol. DM-204 could potentially become the single long-acting treatment by virtue of being a monoclonal antibody therapy”," stated Dr. Mark Williams, Vice President, of Research at DiaMedica. “The chronic in vivo model data shows DM-204’s ability to prevent disease progression of Type 2 diabetes and increased blood pressure.”